Some DD from a newbee yes its dated
Visit the Web site of Ingen Technologies
INGEN TECHNOLOGIES INTRODUCES OXYVIEWTM - OxyViewTM product can earn $200M per year - IGTN prepares for move to OTC:BB -
Ingen Technologies (OTC: IGTN), a medical device manufacturer of OxyAlertTM and Secure BalanceTM announces the new OxyViewTM medical product and $200M annual market just weeks before filing with the SEC and moving to the OTCBB.
With the audits complete, the Company is preparing the necessary SEC filings and move to the OTCBB. "Our auditors, Spector & Wong,LLP in Pasadena-CA have finalized the accounting and audits for IGTN. They are working very close with our lawyers who are preparing the SEC filings. This has been a very strategic move for IGTN, with the audits complete and leaving the pink sheets to become a reporting company on the OTCBB. "All of our shareholders stand to make a very strong return on their investment." Said Scott Sand, CEO & Chairman.
"The market makers have obviously taken advantage of the IGTN stock while on the pink sheets. With the stock value at such a low price, long term investors can jump in now and watch the value of the stock increase 100 fold over the next several months." Said Thomas Neavitt, CFO.
The Company has completed the research & development of another new product; OxyViewTM. This product enhances the safety, assurance and accuracy of hospitalized patients being administered oxygen from any source. OxyViewTM is a lightweight pneumatic gauge that is attached to the oxygen tubing just below the neck. It informs the nursing staff of oxygen flow rate near the patient. It could quickly inform the hospital staff of any leak or inaccuracy between the delivery source and the patient.
Patent Attorney, Donn Harms, of the San Diego-CA based law firm has filed for US Patents on this proprietary technology. "As simple as it sounds, there is nothing in the hospital industry that competes with OxyViewTM. Currently, the hospital staff assumes that the flow rate near the patient is sufficient without any verification. In today’s medical industry where malpractice and liability is a more serious issue, OxyViewTM enhances safety and can reduce liabilities associated with equipment failure." Said Scott Sand, CEO & Chairman.
There are over 20M patients each year that receive oxygen during hospitalization. The OxyViewTM retail price is $75, and is considered a consumable or throw-away item. The company has engaged RC Product Development & Engineering in Corona-CA to build the unit. "This device is completely pneumatic and extremely accurate. We will have production of the unit ready in 3 months." Said Richard Campbell, President of RC Product Development & Engineering.
"Ingen Technologies is strongly positioned to deliver earnings and value to its shareholders. With the current preparation for the SEC filings and move to the OTCBB, OxyViewTM is another asset that will launch the success of this company." Said Scott Sand, CEO & Chairman.
About Ingen Technologies
Ingen Technologies (OTC: IGTN), in business since 1999, is a medical device manufacturer and service provider for medical and consumer markets both domestic and abroad. Increasing revenues are generated from the Company’s Secure BalanceTM program; a medical product line for physicians and hospitals that provide patient services for Balance & Fall Prevention programs. The OxyALERTTM is another product line that has two issued US Patents and is a proprietary technology. This product is the second generation development of the Company’s initial BAFITM product; a medical safety device that provides wireless and remote monitoring of oxygen delivery systems for patients and small aircraft. Using the same patented and proprietary technology, the Company has the GasAlertTM product; a device that interfaces between any gas line and accessory, such as a water heater, dryer, stove or heater, to detect leaks. This is a mass consumer item expected to go to market in 2005.
"Our team of professionals has developed our medical products for the ever increasing elderly population. Our products are superior to any of our competition and they allow for effective medical product availability to seniors, and at the same time the increasing senior population allows for a steady growth in sales and profits"; said Scott Sand, CEO & Chairman of Ingen Technologies.
For more information, visit www.ingen-tech.com
Investor Relations Contact:
Scott R. Sand, C.E.O & Chairman
Ingen Technologies, Inc.
285 E. County Line Road
Calimesa, CA 92320
800-259-9622
951-675-3266
800-777-1186 FAX
scottsand@ingen-tech.com
AI
